论文部分内容阅读
在骨量减少和骨质疏松妇女,口服阿仑膦酸钠10 mg/d,2～3年后可增加腰、髋骨BMD 5％～9％,并减少腰椎和髋骨骨折近50％。但预防骨质疏松,使BMD稳定,5 mg/d较合适。本研究观察在绝经早期具有正常骨密度的妇女,阿仑膦酸钠5 mg/d,连续5年后骨密度及骨代谢标志物,并分析20 mg/d治疗2年者停药后的状况。 选40～59岁,绝经6～36月健康妇女,促卵泡成熟激素(FSH)42～126 IU/L。除外BMD超过年轻正常值±2 SD者,有非创伤性腰、髋骨骨折史,骨代谢异常,近1年内有严重上消化道疾患,曾用二膦酸盐、雌激素、孕激素、降钙素、糖皮质激素、解痉剂和过量VitA、VitD,吸烟>20支/d,饮酒>2杯/d,
In osteopenia and osteoporosis women, oral alendronate 10 mg / d, 2 to 3 years after the waist and hip BMD increased by 5% to 9%, and reduce lumbar and hip fractures by nearly 50%. However, prevention of osteoporosis, BMD stability, 5 mg / d is more appropriate. This study was to observe the women with normal BMD in the early menopause, alendronate 5 mg / d, five years after the bone mineral density and bone metabolism markers, and analysis of 20 mg / d after 2 years of withdrawal status . Select 40 to 59 years of age, 6 to 36 months of menopausal healthy women, follicle stimulating hormone (FSH) 42 ~ 126 IU / L. Except for those with BMD over ± 2 SD younger than normal, there were non-traumatic lumbar and hip fracture and abnormal bone metabolism. Serious upper gastrointestinal disorders occurred in the past year. Bisphosphonates, estrogens, progesterone, Calcium, glucocorticoids, antispasmodic agents and excessive VitA, VitD, smoking> 20 cigarettes / d, drinking> 2 cups / d,